Interrupted time series analysis on first cardiovascular disease hospitalization for adherence to lipid-lowering therapy

被引:7
作者
Hu, Feiyu [1 ]
Warren, Jim [1 ]
Exeter, Daniel J. [2 ]
机构
[1] Univ Auckland, Sch Comp Sci, Private Bag 92019, Auckland, New Zealand
[2] Univ Auckland, Sch Populat Hlth, Auckland, New Zealand
关键词
medication adherence; cardiovascular diseases; interrupted time series analysis; pharmacoepidemiology; MEDICATION ADHERENCE; SECONDARY PREVENTION; MYOCARDIAL-INFARCTION; DIABETES MEDICATIONS; STATIN ADHERENCE; NEW-ZEALAND; NONADHERENCE; IMPACT; RISK; BELIEFS;
D O I
10.1002/pds.4916
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Purpose We analysed lipid-lowering medication adherence before and after the first hospitalization for cardiovascular disease (CVD) to explore the influence hospitalization has on patient medication adherence. Methods We extracted a sub-cohort for analysis from 313,207 patients who had primary CVD risk assessment. Adherence was assessed as proportion of days covered (PDC) >= 80% based on community dispensing records. Adherence in the 4 quarters (360 days) before the first CVD hospitalization and 8 quarters (720 days) after hospital discharge was assessed for each individual in the sub-cohort. An interrupted time series design using generalized estimating equations was applied to compare the differences of population-level medication adherence rates before and after the first CVD hospitalization. Results Overall, a significant improvement in medication adherence rate from before to after the hospitalization was observed (odds ratio (OR) 2.49 [1.74-3.57]) among the 946 patients included in the analysis. Patients having diabetes history had a higher OR of adherence before the hospitalization than patients without diabetes (1.50 [1.03-2.22]) but no significant difference after the hospitalization (OR 1.13 [0.89-1.43]). Before the first hospitalization, we observed that quarterly medication adherence rate was steady at around 55% (OR 0.97 [0.93-1.01), whereas the trend in adherence over the post-hospitalization period decreased significantly per quarter (OR 0.97 [0.94-0.99]). Conclusions Patients were more likely to adhere to lipid-lowering therapy after experiencing a first CVD hospitalization. The change in medication adherence rate is consistent with patients having heightened perception of disease severity following the hospitalization.
引用
收藏
页码:150 / 160
页数:11
相关论文
共 50 条
[21]   Electronic messaging support service programs improve adherence to lipid-lowering therapy among outpatients with coronary artery disease: an exploratory randomised control study [J].
Fang, Ronghua ;
Li, Xia .
JOURNAL OF CLINICAL NURSING, 2016, 25 (5-6) :664-671
[22]   Retrospective real-world analysis of adherence and persistence to lipid-lowering therapy in Germany [J].
Koenig, Wolfgang ;
Lorenz, Elke S. ;
Beier, Lea ;
Gouni-Berthold, Ioanna .
CLINICAL RESEARCH IN CARDIOLOGY, 2024, 113 (06) :812-821
[23]   Reinforcing adherence to lipid-lowering therapy after an acute coronary syndrome: A pragmatic randomized controlled trial [J].
Zafeiropoulos, Stefanos ;
Farmakis, Ioannis ;
Kartas, Anastasios ;
Arvanitaki, Alexandra ;
Pagiantza, Areti ;
Boulmpou, Aristi ;
Tampaki, Athina ;
Kosmidis, Diamantis ;
Nevras, Vassileios ;
Markidis, Eleftherios ;
Papadimitriou, Ioannis ;
Vlachou, Anastasia ;
Arvanitakis, Konstantinos ;
Miyara, Santiago J. ;
Ziakas, Antonios ;
Molmenti, Ernesto P. ;
Kassimis, George ;
Zanos, Stavros ;
Karvounis, Haralambos ;
Giannakoulas, George .
ATHEROSCLEROSIS, 2021, 323 :37-43
[24]   Moving toward combination lipid-lowering therapy for all patients with atherosclerotic cardiovascular disease [J].
Faridi, Kamil F. ;
Desai, Nihar R. .
AMERICAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2023, 14
[25]   Comparison of the European and US guidelines for lipid-lowering therapy in primary prevention of cardiovascular disease [J].
Delabays, Benoit ;
de La Harpe, Roxane ;
Vollenweider, Peter ;
Fournier, Stephane ;
Muller, Olivier ;
Strambo, Davide ;
Graham, Ian ;
Visseren, Frank L. J. ;
Nanchen, David ;
Marques-Vidal, Pedro ;
Vaucher, Julien .
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2023, 30 (17) :1856-1864
[26]   Lipid-lowering therapy and patient adherence in the MULTI GAP 2013 trial [J].
Gabor, Simonyi .
ORVOSI HETILAP, 2014, 155 (17) :669-675
[27]   Landmark Lipid-Lowering Trials in the Primary Prevention of Cardiovascular Disease [J].
Chrispin, Jonathan ;
Martin, Seth S. ;
Hasan, Rani K. ;
Joshi, Parag H. ;
Minder, C. Michael ;
McEvoy, John W. ;
Kohli, Payal ;
Johnson, Amber E. ;
Wang, Libin ;
Blaha, Michael J. ;
Blumenthal, Roger S. .
CLINICAL CARDIOLOGY, 2013, 36 (09) :516-523
[28]   Comparative effectiveness of lipid-lowering treatments to reduce cardiovascular disease [J].
Suh, Dong-Churl ;
Griggs, Scott K. ;
Henderson, Emmett R. ;
Lee, Seung-Mi ;
Park, Taehwan .
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2018, 18 (01) :51-69
[29]   Time to benefit of intensive lipid lowering therapy in individuals with cardiovascular disease [J].
Li, Linjie ;
Huang, Chuanyi ;
Liu, Wennan ;
Li, Jingge ;
Geru, A. ;
Chen, Xiaozhi ;
Jiang, Shichen ;
Fang, Yiwen ;
Foo, Roger Sik-Yin ;
Chan, Mark Yan-Yee ;
Yu, Ying ;
Li, Yongle ;
Yang, Qing ;
Zhou, Xin .
JOURNAL OF CLINICAL LIPIDOLOGY, 2025, 19 (01) :51-59
[30]   Meta-Analysis of Intensive Lipid-Lowering Therapy in Patients With Polyvascular Disease [J].
Alkhalil, Mohammad ;
Kuzemczak, Michal ;
Whitehead, Nicholas ;
Kavvouras, Charalampos ;
Dzavik, Vladimir .
JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2021, 10 (05) :1-10